Product development
Sophiris is focused on the development of PRX302, a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate). PRX302, currently in Phase II clinical trials, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments.